Karyopharm Therapeutics Inc.

NasdaqGS:KPTI Stock Report

Market Cap: US$126.9m

Karyopharm Therapeutics Past Earnings Performance

Past criteria checks 0/6

Key information

10.3%

Earnings growth rate

21.0%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate31.6%
Return on equityn/a
Net Margin-98.0%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 33%

Feb 23
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 33%

Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)

Feb 05

Improved Revenues Required Before Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock's 27% Jump Looks Justified

Apr 17
Improved Revenues Required Before Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock's 27% Jump Looks Justified

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Apr 17
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Karyopharm: Market Is Overlooking Growth

Oct 07

Karyopharm Therapeutics Q2 2022 Earnings Preview

Aug 03

Karyopharm cancer therapy eltanexor gets FDA fast track status, orphan drug tag in EU

Jul 20

Karyopharm: Another 2 Year Wait For Data

May 05

Karyopharm: Opportunity To Buy Based On Latest Endometrial Cancer Data And Xpovio Sales Estimates

Feb 19

Karyopharm Therapeutics: Unjustified Sell-Off Provides An Opportunity To Reload My Position

Dec 04

Karyopharm Therapeutics: After Years Of Waiting I'm Ready To Join The Bulls

Sep 16

Analyst Forecasts Just Became More Bearish On Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Aug 07
Analyst Forecasts Just Became More Bearish On Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Revenue & Expenses Breakdown
Beta

How Karyopharm Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:KPTI Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23146-143132139
30 Sep 23146-140134141
30 Jun 23146-142134141
31 Mar 23148-158137141
31 Dec 22157-165145149
30 Sep 22250-88142152
30 Jun 22251-104146161
31 Mar 22234-108145161
31 Dec 21210-124144161
30 Sep 21119-20614311
30 Jun 21102-20813910
31 Mar 21113-20113310
31 Dec 20108-196126151
30 Sep 2091-2011218
30 Jun 2083-1891150
31 Mar 2059-1861090
31 Dec 1941-2001056
30 Sep 1923-209960
30 Jun 1910-216840
31 Mar 1920-206680
31 Dec 1830-178490
30 Sep 1832-159360
30 Jun 1831-142290
31 Mar 1812-138260
31 Dec 172-129250
30 Sep 170-117250
30 Jun 170-112250
31 Mar 170-112250
31 Dec 160-110240
30 Sep 160-112230
30 Jun 160-117220
31 Mar 160-119220
31 Dec 150-118220
30 Sep 150-115220
30 Jun 150-104210
31 Mar 150-88180
31 Dec 140-76160
30 Sep 140-62130
30 Jun 140-52100
31 Mar 140-4280
31 Dec 130-3460
30 Sep 130-2640
30 Jun 130-2030

Quality Earnings: KPTI is currently unprofitable.

Growing Profit Margin: KPTI is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: KPTI is unprofitable, but has reduced losses over the past 5 years at a rate of 10.3% per year.

Accelerating Growth: Unable to compare KPTI's earnings growth over the past year to its 5-year average as it is currently unprofitable


Return on Equity


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.